Samsung Biologics Buys GSK's US Plant for $280 Million

The South Korean pharmaceutical contract manufacturer acquires its first US production facility. The plant is expected to have a total capacity of 60,000 liters for pharmaceuticals.

, and Administrator

2025 December 22 . 7:12 AM

1 min read

This image is clicked in a room, where it looks like Store. There are so many bottles in this image... — This image is clicked in a room, where it looks like Store. There are so many bottles in this image and cans. There is a Banner in the middle which is indicating Supra brand. Bottom right corner there is a logo LM.

Samsung Biologics Buys GSK's US Plant for $280 Million

Samsung Biologics has agreed to buy its first US production facility from pharmaceutical giant GSK. The deal, valued at $280 million, will see the South Korean firm take over a major manufacturing site in Rockville, Maryland. Completion of the purchase is expected by the end of the first quarter of 2026.

The Rockville facility currently has a total production capacity of 60,000 litres for drug substances. Samsung Biologics has confirmed plans to expand this capacity after the acquisition. Alongside increasing output, the company will also invest in upgrading the site’s technology.

The move marks Samsung Biologics’ first direct manufacturing presence in the US. Once the deal closes, the company intends to strengthen its position in the global biopharmaceutical market. The facility’s existing infrastructure will provide a foundation for further growth.

The acquisition will cost Samsung Biologics $280 million, with the transaction set to finalise by early 2026. After taking control, the company will focus on expanding production and modernising equipment at the Maryland plant. This step follows the firm’s strategy to increase its international manufacturing capabilities.